Trial · NCT01358877
Adverse events1,200
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,200
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 667 | 2,364 | 833 |
| other | ANAEMIA | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 567 | 2,405 | 717 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 220 | 2,364 | 484 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 235 | 2,405 | 535 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 592 | 2,364 | 1,039 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 556 | 2,405 | 1,007 |
| other | DRY EYE | Eye disorders | Pertuzumab + Trastuzumab + Chemotherapy | 141 | 2,364 | 146 |
| other | DRY EYE | Eye disorders | Placebo + Trastuzumab + Chemotherapy | 113 | 2,405 | 118 |
| other | LACRIMATION INCREASED | Eye disorders | Pertuzumab + Trastuzumab + Chemotherapy | 312 | 2,364 | 334 |
| other | LACRIMATION INCREASED | Eye disorders | Placebo + Trastuzumab + Chemotherapy | 324 | 2,405 | 347 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Pertuzumab + Trastuzumab + Chemotherapy | 285 | 2,364 | 369 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo + Trastuzumab + Chemotherapy | 261 | 2,405 | 337 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | Pertuzumab + Trastuzumab + Chemotherapy | 244 | 2,364 | 304 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | Placebo + Trastuzumab + Chemotherapy | 220 | 2,405 | 297 |
| other | CONSTIPATION | Gastrointestinal disorders | Pertuzumab + Trastuzumab + Chemotherapy | 692 | 2,364 | 1,028 |
| other | CONSTIPATION | Gastrointestinal disorders | Placebo + Trastuzumab + Chemotherapy | 762 | 2,405 | 1,117 |
| other | DIARRHOEA | Gastrointestinal disorders | Pertuzumab + Trastuzumab + Chemotherapy | 1,667 | 2,364 | 3,368 |
| other | DIARRHOEA | Gastrointestinal disorders | Placebo + Trastuzumab + Chemotherapy | 1,091 | 2,405 | 1,791 |
| other | DRY MOUTH | Gastrointestinal disorders | Pertuzumab + Trastuzumab + Chemotherapy | 150 | 2,364 | 166 |
| other | DRY MOUTH | Gastrointestinal disorders | Placebo + Trastuzumab + Chemotherapy | 140 | 2,405 | 176 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01358877/events